California Defective Drug Lawyer: Brand-Name vs. Generic Preemption, Conte Innovator Liability, and Current MDL Framework

HOME › CALIFORNIA PERSONAL INJURY › PRODUCT LIABILITY AND ABUSE › DEFECTIVE DRUG

Last updated: April 2026 — Reflects California strict product liability doctrine under Greenman v. Yuba Power Products, Inc. (1963) 59 Cal.2d 57, the U.S. Supreme Court's pharmaceutical preemption framework under Wyeth v. Levine (2009) 555 U.S. 555, PLIVA, Inc. v. Mensing 

California defective drug litigation operates within a tightly layered federal and state legal framework. Federal preemption doctrine, refined through four U.S. Supreme Court decisions between 2009 and 2019, determines which categories of failure-to-warn and design defect claims can proceed against pharmaceutical manufacturers.

California's unique innovator liability doctrine under Conte v. Wyeth preserves brand-name manufacturer exposure for generic drug injuries — a minority position that provides plaintiffs critical recourse unavailable in most other states.

The practical choice among federal MDL consolidation, California JCCP proceedings, and individual state-court litigation determines venue, timing, and strategic posture. For the broader product liability and abuse framework, see our California Product Liability and Abuse guide.

The stakes in California defective drug litigation have grown substantially in the current cycle. Active MDL proceedings address GLP-1 agonist complications (Ozempic, Wegovy, Mounjaro), hair relaxers and uterine cancer, Tylenol and autism/ADHD (currently subject to preemption challenges), Zantac and NDMA contamination, and numerous other active cases.

California plaintiffs benefit from the Conte doctrine, the favorable California discovery rule under CCP § 340.8 for toxic exposure, and the strong plaintiff venue options in both state and federal courts.

California Strict Product Liability Framework

California recognized strict product liability in Greenman v. Yuba Power Products, Inc. (1963) 59 Cal.2d 57, establishing the doctrine that a manufacturer is strictly liable when a product it has placed on the market, knowing that it will be used without inspection for defects, proves to have a defect that causes injury. The California framework recognizes three distinct categories of product defect:

Manufacturing defects — the product departs from its intended design, typically due to quality control failures. In drug cases, this includes contamination (the Zantac NDMA contamination pattern), potency errors, mislabeled batches, and similar manufacturing failures. Manufacturing defect claims are generally not subject to federal preemption because they do not challenge the FDA-approved formula or label.

Design defects — the product's design itself is unreasonably dangerous. California applies two alternative tests under Barker v. Lull Engineering Co. (1978) 20 Cal.3d 413: the consumer expectation test (the product failed to perform as safely as an ordinary consumer would expect) and the risk-benefit test (the risks of the design outweigh its benefits).

In drug cases, design defect claims face particular doctrinal challenges under Brown v. Superior Court (1988) 44 Cal. 3d 1049, which limited design defect claims against prescription drugs, and federal preemption challenges under Mutual Pharmaceutical v. Bartlett for generic drugs.

Warning defects (failure-to-warn) — the product lacks adequate warnings about known or knowable risks. Warning defect claims are the primary vehicle for defective drug litigation, because most injuries arise from adequately manufactured drugs with design properties the FDA approved, but with warnings that failed to adequately disclose risks.

The California strict liability framework applies to manufacturers, distributors, retailers, and other entities in the chain of distribution. The scope of available defendants varies depending on the nature of the defect and the federal preemption analysis.

Federal Preemption Framework — The Four Supreme Court Decisions

The U.S. Supreme Court has issued four decisions between 2009 and 2019 that have shaped federal preemption of state-law pharmaceutical claims. Each decision addresses a specific category of claim with a distinctive preemption analysis.

Wyeth v. Levine (2009) — Brand-Name Drug Failure-to-Warn (Not Preempted). The Court held that state law failure-to-warn claims against brand-name drug manufacturers are generally not preempted because brand-name manufacturers can unilaterally strengthen warnings through the FDA's Changes Being Effected (CBE) process under 21 CFR § 314.70.

The manufacturer "bears responsibility for the content of its label at all times," and the ability to strengthen warnings unilaterally means that compliance with both state and federal law is possible.

The Court created a narrow "clear evidence" exception: preemption applies if the manufacturer shows clear evidence that the FDA would not have approved the proposed label change.

PLIVA, Inc. v. Mensing (2011) — Generic Drug Failure-to-Warn (Preempted).

The Court held that state law failure-to-warn claims against generic drug manufacturers are preempted. Federal law requires generic drugs to have the same labeling as the brand-name drug (the "duty of sameness" under the Hatch-Waxman Act), and generic manufacturers cannot unilaterally change warnings.

Because compliance with a state-law duty to strengthen warnings would violate the federal duty of sameness, the claims are preempted under the impossibility preemption doctrine.

Mutual Pharmaceutical Co. v. Bartlett (2013) — Generic Drug Design Defect (Preempted). The Court extended Mensing's impossibility preemption analysis to generic drug design defect claims. Federal law requires generic drugs to have the same active ingredients, route of administration, dosage form, strength, and labeling as the brand-name drug. Because the generic manufacturer cannot redesign the drug without violating federal law, state-law design-defect claims are preempted.

Merck Sharp & Dohme Corp. v. Albrecht (2019) — Clarifying Wyeth's "Clear Evidence" Standard. The Court clarified that the "clear evidence" preemption question is a legal question for the judge (not a factual question for the jury), and that "clear evidence" means clear evidence that the FDA would have rejected the manufacturer's proposed label change. The decision narrowed the preemption defense in brand-name drug cases by placing the burden of proof squarely on the manufacturer to produce concrete evidence of FDA rejection.

California Preemption Framework — 2026

Claim Category	Brand-Name Drug	Generic Drug
Manufacturing defect	Not preempted	Not preempted
Design defect (prescription drugs)	Subject to Brown v. Superior Court limitations, not generally preempted	Preempted under Bartlett
Failure-to-warn	Not preempted (subject to Wyeth/Albrecht "clear evidence" defense)	Preempted under Mensing
Breach of express warranty	Not preempted	Not preempted (narrow)
Negligent misrepresentation	Not preempted	Not preempted (foreign state distinction from innovator liability)

The federal preemption framework creates a significant asymmetry: brand-name drug manufacturers face substantial failure-to-warn exposure under California tort law, while generic drug manufacturers largely do not. This asymmetry drove the development of California's unique innovator liability doctrine.

California's Conte v. Wyeth Innovator Liability Doctrine

California is one of the few states that recognizes innovator liability — the doctrine under which brand-name drug manufacturers can be liable for injuries caused by generic versions of their drugs under theories of negligent misrepresentation.

In Conte v. Wyeth, Inc. (2008) 168 Cal.App.4th 89, the California Court of Appeals held that a brand-name drug manufacturer's duty extends "not only to consumers of its own product, but also to those whose doctors foreseeably rely on the name-brand manufacturer's product information when prescribing a medication, even if the prescription is filled with the generic version of the prescribed drug."

The court reasoned that prescribing physicians rely on brand-name manufacturers' warnings regardless of whether the ultimate prescription is filled with a brand-name or generic product, and that brand-name manufacturers create the warnings that control both brand-name and generic labeling.

The Conte doctrine provides California plaintiffs a critical recourse that most other states deny. When a generic drug causes injury, and Mensing preempts the direct failure-to-warn claim against the generic manufacturer, the plaintiff can still pursue the brand-name manufacturer under Conte for negligent misrepresentation based on the warnings that controlled the generic labeling.

The Conte doctrine has faced substantial pushback outside California — most states have rejected it, including the Iowa Supreme Court in Huck v. Wyeth (2014), and most federal circuits have applied other states' laws.

Within California, however, Conte remains a binding precedent. Plaintiffs pursuing generic drug claims in California state court or in federal court applying California law retain the innovator liability theory as a primary recovery pathway.

Learned Intermediary Doctrine

The learned intermediary doctrine, recognized in California under Carlin v. Superior Court (1996) 13 Cal.4th 1104, provides that drug manufacturers satisfy their warning duty by adequately informing the prescribing physician rather than the patient directly. The physician is the "learned intermediary" who translates drug information into specific prescribing decisions for individual patients.

The practical effect in California defective drug litigation is that:

• Warnings in the package insert, Physician Reference (formerly PDR), and promotional materials to physicians are the primary relevant warnings, not direct-to-patient information

• Failure-to-warn claims focus on what the prescribing physician knew or should have known, based on what the manufacturer communicated

• Expert testimony from the prescribing physician about whether stronger warnings would have changed the prescribing decision is typically central to causation

• Direct-to-consumer advertising erodes the learned intermediary defense under Perez v. Wyeth Laboratories Inc. (1999) 161 N.J. 1 (persuasive in California though not binding) when the manufacturer markets directly to consumers

The learned intermediary defense is substantive, not procedural — plaintiffs must address it affirmatively in their case development by taking depositions of prescribing physicians and conducting expert analysis of warning adequacy.

Vaccine Preemption Under Bruesewitz

Vaccine cases face a distinctive preemption framework under Bruesewitz v. Wyeth, LLC (2011) 562 U.S. 223. The Court held that the National Childhood Vaccine Injury Act (NCVIA) preempts state-law design-defect claims against vaccine manufacturers.

The NCVIA creates the National Vaccine Injury Compensation Program (VICP) — a no-fault compensation system administered by the Court of Federal Claims — as the primary remedy for vaccine injuries.

Practical implications for California plaintiffs:

• State law design defect claims against vaccine manufacturers are not available

• The VICP administrative claim process is the first step for most vaccine injury cases

• If the VICP denies compensation or the petitioner rejects the VICP compensation offer, civil litigation in state or federal court proceeds with limited claim categories (manufacturing defect, failure-to-warn with FDA preemption analysis, negligent conduct outside VICP's scope)

• COVID-19 vaccines are covered by the PREP Act framework rather than NCVIA, with even more restrictive liability exposure

Vaccine cases require specialized counsel familiar with both VICP practice and the narrow civil litigation pathways that remain available.

California Drug Cases in Current Litigation

The current California defective drug landscape includes several active high-volume categories.

GLP-1 agonists (Ozempic, Wegovy, Mounjaro, Zepbound). MDL 3094 in the Eastern District of Pennsylvania consolidates gastroparesis, intestinal obstruction, and related gastrointestinal complication claims. California plaintiffs routinely appear in both the federal MDL and parallel California state court proceedings.

Hair relaxers and uterine cancer. MDL 3060 in the Northern District of Illinois addresses claims that chemical hair relaxers, used predominantly by Black women, contributed to uterine cancer, ovarian cancer, and uterine fibroids. The litigation involves manufacturing defect, design defect, and failure-to-warn theories against manufacturers including L'Oréal, SoftSheen-Carson, Strength of Nature, and others.

Tylenol (acetaminophen) and autism/ADHD. MDL 3043 addresses claims that prenatal acetaminophen exposure contributes to autism and ADHD in children. The MDL faces significant Daubert challenges on causation expert testimony and preemption defenses. California plaintiffs participate in the federal MDL.

Zantac (ranitidine) and NDMA contamination. Manufacturing defect claims arising from NDMA contamination in ranitidine. Federal MDL 2924 resolved many claims through settlement, but California state court litigation continues through the coordinated proceedings.

Opioid manufacturers. Substantial opioid litigation continues under federal MDL 2804 and California state court proceedings. California settlements with major manufacturers have produced substantial recoveries for state and local governments; individual injury cases proceed in parallel.

Elmiron (pentosan polysulfate sodium). Vision injury claims arising from long-term Elmiron use for interstitial cystitis. MDL 2973 in the District of New Jersey consolidates cases.

Paraquat herbicide and Parkinson's disease. Not a pharmaceutical but relevant as a parallel toxic exposure framework. MDL 3004 consolidates Parkinson's disease claims against Syngenta and Chevron.

SSRI antidepressants and birth defects. Ongoing litigation against various SSRI manufacturers for birth defects and neurodevelopmental outcomes.

Roundup (glyphosate) and non-Hodgkin lymphoma. Active federal preemption review at the U.S. Supreme Court as of April 2026, with implications extending to pharmaceutical preemption doctrine generally.

MDL, JCCP, and Individual Litigation

California defective drug plaintiffs face several venue and procedural options.

Federal Multidistrict Litigation (MDL). The Judicial Panel on Multidistrict Litigation consolidates related federal cases before a single judge for coordinated pretrial proceedings, including discovery, motion practice, and bellwether trials.

California plaintiffs whose cases qualify for MDL can file directly in the MDL district or file in California federal court and be transferred to the MDL. Settlement in MDL cases typically occurs through aggregate settlement programs with individual case valuations.

California Judicial Council Coordination Proceeding (JCCP). California's state court equivalent of the federal MDL, governed by CCP § 404 et seq. JCCP consolidates related California state court cases before a single judge. Pharmaceutical cases with substantial California state court exposure routinely proceed through JCCP. Benefits include California discovery rules, state-specific substantive law application, and jury pools often favorable to plaintiffs.

Individual state court litigation. Plaintiffs may pursue individual cases in California state court, particularly when the case does not qualify for MDL or JCCP consolidation, or when strategic reasons (strong individual case facts, willingness to try the case, preference for state court jury pools) favor individual litigation.

Class action. Traditional class actions under Federal Rule 23 or California CCP § 382 are rare in modern pharmaceutical litigation because individual damages and causation vary substantially among plaintiffs. Most current pharmaceutical cases proceed as MDL or JCCP consolidations rather than class actions.

The venue choice has substantial implications for discovery, applicable law, trial timing, and settlement leverage. Experienced counsel evaluates each case's facts against current MDL and JCCP proceedings to identify the optimal pathway.

Damages in California Defective Drug Cases

Damages in California defective drug cases include the standard categories with specific applications.

Economic damages include past and future medical expenses (often substantial in cases involving serious complications requiring ongoing treatment), lost earnings and earning capacity, and other quantifiable economic losses. Life care planning testimony is standard in cases involving permanent injury or disability.

Non-economic damages include pain and suffering, emotional distress, disfigurement (relevant in cases involving scarring or physical appearance changes), and loss of enjoyment of life. California non-economic damages are uncapped in product liability cases — MICRA applies only to medical malpractice, not to products liability claims against manufacturers.

Punitive damages under Civil Code § 3294 are available when the manufacturer's conduct meets the malice, oppression, or fraud standard. Pharmaceutical punitive damages cases frequently involve documented evidence that manufacturers knew of serious risks but concealed them, continued marketing despite adverse event reports, or suppressed scientific evidence. Substantial punitive damages verdicts are recurring in pharmaceutical litigation.

Wrongful death and survival damages in fatal cases. For the wrongful death framework applicable when a defective drug causes death, see our California Product Liability Wrongful Death guide. Survival action damages under CCP § 377.30 are available for the decedent's economic damages (medical expenses, lost earnings); pre-death pain and suffering is no longer recoverable in survival actions filed on or after January 1, 2026 following the SB 447 sunset — see our California Survival Action guide for the post-sunset framework.

Statute of Limitations

Ordinary product liability claims: Two years from the date of injury under CCP § 335.1.

Toxic exposure and delayed discovery: Two years from the date of discovery under CCP § 340.8, which provides specifically that a civil action for injury from exposure to a hazardous material or toxic substance must be filed within two years from the date of injury or the date the plaintiff became aware (or reasonably should have become aware) both of the injury and its cause, whichever is later. Section 340.8 is central in long-latency drug cases where the connection between the drug and the injury emerges years after exposure.

Wrongful death: Two years from the date of death under CCP § 335.1 for the wrongful death cause of action.

Survival action: The longer of two years from death or six months after death if the personal injury limitations period had not expired at death, under CCP § 366.1.

Federal claims: Some federal claims have separate limitations periods, particularly in MDL proceedings.

The interaction between the two-year ordinary statute and the delayed discovery rule under § 340.8 is particularly important in pharmaceutical cases. Plaintiffs who developed injuries years after taking a drug, and who only later discovered the causal connection through FDA adverse event reports, medical journal publications, or litigation disclosures, retain filing rights under § 340.8's discovery rule.

Proving California Defective Drug Claims

The proof framework in California defective drug cases typically involves several layers of expert testimony and documentary evidence.

Product identification. Establishing that the plaintiff was exposed to the specific product at issue. Pharmacy records, medical records, and in some cases physical possession of the product (for manufacturing defect cases) support identification. Generic drug cases frequently involve identification challenges because multiple manufacturers produce the same generic drug.

Medical causation. Expert testimony establishing that the drug caused or contributed to the plaintiff's injury. Causation expert testimony is frequently the central battleground in pharmaceutical litigation, with extensive Daubert (federal) or Sargon (California under Sargon Enterprises, Inc. v. University of Southern California (2012) 55 Cal.4th 747) expert testimony challenges on the reliability of the plaintiff's causation methodology.

Warning inadequacy. Expert testimony and documentary evidence establishing that the manufacturer's warnings failed to adequately disclose the risks known or knowable to the manufacturer. Internal company documents, adverse event reports, scientific literature, and FDA correspondence are typically central. Regulatory experts frequently testify about industry standards for warning content and updating.

Alternative feasibility (design defect cases). Expert testimony establishing that a feasible alternative design would have prevented the injury without rendering the drug unsuitable for its intended use. Design defect claims face particular challenges under Brown v. Superior Court in prescription drug cases.

Manufacturer knowledge and misconduct. Internal documents, email correspondence, adverse event reports, FDA correspondence, and witness testimony establishing what the manufacturer knew about the risks, when they knew it, and how they responded. These records support failure-to-warn claims, punitive damages claims, and preemption defense challenges.

What to Do If You Were Injured by a Prescription Drug in California

Preserve the product and its packaging if available. Physical preservation of the product, including pill bottles, package inserts, and any remaining medication, is critical in manufacturing defect cases.

Obtain complete medical records. Records showing the prescription, administration, dosing history, and development of the injury establish the temporal sequence central to causation. Records from all treating physicians are relevant.

Obtain complete pharmacy records. Pharmacy records identify the specific manufacturer and batch of the drug actually dispensed — particularly important in generic drug cases where multiple manufacturers may have produced the medication.

Document the progression of the injury. Photographs, journal entries, and contemporaneous records of symptom development, treatment responses, and functional limitations support both causation and damages.

Research FDA adverse event reports and recalls. The FDA Adverse Event Reporting System (FAERS) database, FDA recall announcements, and FDA safety communications provide documentary evidence of known risks and manufacturer knowledge.

Identify active MDL or JCCP proceedings. For widely-used drugs with known complication patterns, existing MDL or JCCP proceedings may already address the injury category. Identification of active consolidation enables coordination with specialized counsel.

Consult with specialized pharmaceutical litigation counsel early. Pharmaceutical litigation is specialized practice requiring familiarity with federal preemption doctrine, California's Conte innovator liability framework, MDL and JCCP practice, and the specific medical and regulatory landscape of the drug at issue. Early consultation preserves evidence and identifies the optimal venue and strategy.

Preserve electronic records. Communications with healthcare providers about the medication, any patient support materials from the manufacturer, and any direct-to-consumer advertising encountered may be relevant to the learned intermediary analysis.

Understand the litigation timeline. Pharmaceutical cases typically require 24–48 months from filing to resolution, with MDL and JCCP proceedings often requiring longer for bellwether trials and aggregate settlement development. Patient coordination with ongoing medical treatment is essential.

Frequently Asked Questions

Can I sue a drug manufacturer in California? Yes, when the drug caused injury through a manufacturing defect, design defect (subject to limitations under Brown v. Superior Court for prescription drugs), or failure-to-warn. The availability of specific claims depends on whether the drug is brand-name or generic, the nature of the alleged defect, and whether federal preemption applies. California's Conte v. Wyeth doctrine uniquely permits claims against brand-name manufacturers for injuries caused by generic versions of their drugs under negligent misrepresentation theories.

What is the difference between brand-name and generic drug litigation in California? Brand-name drug failure-to-warn claims are not preempted under Wyeth v. Levine, subject to the narrow "clear evidence" defense clarified by Merck v. Albrecht. Generic drug failure-to-warn claims are preempted under PLIVA v. Mensing, and generic drug design defect claims are preempted under Mutual Pharmaceutical v. Bartlett. California plaintiffs injured by generic drugs retain recourse against brand-name manufacturers under the Conte v. Wyeth innovator liability doctrine.

What is an MDL, and do California plaintiffs participate? A multidistrict litigation (MDL) is a federal consolidation of related cases before a single judge for coordinated pretrial proceedings. California plaintiffs routinely participate in pharmaceutical MDLs, either by direct filing in the MDL district or by filing in California federal court and being transferred. California state court cases are often coordinated in parallel through the California JCCP framework under CCP § 404.

Are punitive damages available in California defective drug cases? Yes, when the manufacturer's conduct meets the malice, oppression, or fraud standard under Civil Code § 3294. Pharmaceutical punitive damages cases frequently involve documented evidence that manufacturers knew of serious risks but concealed them, continued marketing despite adverse event reports, or suppressed scientific evidence. Substantial punitive damages verdicts are recurring in pharmaceutical litigation.

Does the MICRA cap apply to California defective drug cases? No. MICRA applies only to medical malpractice claims against healthcare providers. Product liability claims against pharmaceutical manufacturers are not subject to MICRA caps. Economic and non-economic damages in California pharmaceutical litigation are uncapped.

What is the statute of limitations for California defective drug claims? Two years from the date of injury under CCP § 335.1 for ordinary claims. Toxic exposure and delayed-discovery cases are governed by CCP § 340.8, which allows filing within two years from the date the plaintiff became aware (or reasonably should have become aware) of both the injury and its cause. The delayed discovery rule is particularly important in long-latency drug cases where the causal connection emerges years after exposure.

Can I sue for a drug recall even if I didn't have an immediate reaction? Potentially, depending on the nature of the recall and your specific use of the drug. Class I recalls involve serious risks and may support claims even without immediate symptoms if future monitoring or treatment costs are anticipated. Class II and Class III recalls address less serious issues. Early consultation with counsel allows evaluation of whether the recall facts support an individual or consolidated claim.

DISCLOSURE 

This page is published and maintained by 1000Attorneys.com, a California State Bar Certified Lawyer Referral and Information Service, LRIS Certificate No. 0128, accredited by the American Bar Association and established in 2005. The information on this page is for general educational purposes only and is not legal advice. 1000Attorneys.com is not a law firm and does not provide legal representation. For legal advice about your specific situation, consult a qualified California attorney licensed to practice in the jurisdiction where your claim arises.